BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia

N Engl J Med. 2007 Jul 19;357(3):258-65. doi: 10.1056/NEJMct071828.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Benzamides
  • Dasatinib
  • Female
  • Fusion Proteins, bcr-abl
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / physiopathology
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Practice Guidelines as Topic
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use

Substances

  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • Dasatinib